Drugs / Nivo800
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07460765 | Jul 2026 → Apr 2030 expected | oral cavity squamous cell carcinoma | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nivo800 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07460765 ↗ |
| Known as | nivolumab-IRDye800CW | “evaluate the safety and feasibility of nivolumab-IRDye800CW (nivo800) as a molecular imaging agent in adults with biopsy-confirmed or presumed head and neck squamous cell...” NCT07460765 ↗ |
| Modality | Diagnostic / imaging agent | “as a molecular imaging agent” NCT07460765 ↗ |
| Route | Intravenous | “two intravenous infusions during the preoperative period” NCT07460765 ↗ |